Bristol-myers Squibb Compnay

Abbvie Inc.

Other

Receptos, Inc.

Celgene International Ii Sarl

Abbvie Manufacturing Management Unlimited Company

Robert Peach

Han Chang

Glen Eugene Mikesell

Peter S Linsley

Jurgen Bajorath

Joseph Naemura

Jean-Claude Becker

David Hagerty

Robert Cohen

Fiona Lorraine Scott

Suzette Belder-Carr

Suzette Carr

Jeffrey A Ledbetter

Esther Martinborough

Marcus F Boehm

Liming Huang

Adam Richard Yeager

Junko Tamiya

Manisha Moorjani

Enugurthi Brahmachary

Michael Allen Hanson

Joshua N Finger

Jennifer L Brooks

Guchen Yang

Gregg Alan Timony

Gregg Timony

Sheila Gujrathi

Henry Shen

Allan Olson

William Brady

Christian P Larsen

Thomas C Pearson

Andrew B Adams

Nitin Krishnaji Damle

Philip M Wallace

Kristen R Taylor Meadows

John R Peach

Robert H McClure

The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.

Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies

The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an inter leukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.

Methods for treatment of systemic lupus erythematosus (SLE' or 'Lupus') by administration of a modulator of sphingosine-1-phosphate receptor subtype 1 (S1P1), as well as compositions and methods related to the same, wherein such S1P1 modulators have the following general structure and wherein X and Y are as defined herein. 

Compounds and methods for treating lupus

The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.

BSL2v2c2-Ig polypeptides

B7-related nucleic acids and polypeptides useful for immunomodulation

The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

Methods of treatment using CTLA4 mutant molecules

Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.

Methods for treating dermatomyositis or polymyositis by administering a soluble CTLA4 molecule

Polynucleotides encoding BSL2v2c2

Polynucleotides encoding BSL2v2c2-Ig

The present invention relates to compositions and methods for treating autoimmune diseases, such as scleroderma, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.

Methods for treating scleroderma by administering a soluble CTLA4 molecule

Growing community of inventors

San Diego, CA, United States of America

Robert Peach